Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy,safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study 期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy,safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study

摘要：